litlas
Log inCreate account

Mark C. Genovese

Active 1991–2026

Also published as
Mark C Genovese
131
Papers
28,679
Citations
89
h-index
128
i10-index

Citations

Citations per year for Mark C. Genovese1974: 1 citations1986: 4 citations1987: 3 citations1991: 2 citations1992: 1 citations1993: 2 citations1994: 3 citations1995: 3 citations1996: 4 citations1997: 4 citations1998: 7 citations1999: 5 citations2000: 10 citations2001: 56 citations2002: 147 citations2003: 198 citations2004: 196 citations2005: 187 citations2006: 215 citations2007: 196 citations2008: 235 citations2009: 272 citations2010: 328 citations2011: 315 citations2012: 293 citations2013: 282 citations2014: 257 citations2015: 310 citations2016: 256 citations2017: 334 citations2018: 308 citations2019: 788 citations2020: 1,051 citations2021: 887 citations2022: 743 citations2023: 543 citations2024: 783 citations2025: 390 citations2026: 7 citations1975–1985: no citations, so these years are not shown1988–1990: no citations, so these years are not shown

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 2,910 citing papers, 24.1% of this breakdownUnited Kingdom: 1,076 citing papers, 8.9% of this breakdownGermany: 761 citing papers, 6.3% of this breakdownChina: 621 citing papers, 5.1% of this breakdownItaly: 542 citing papers, 4.5% of this breakdownCanada: 536 citing papers, 4.4% of this breakdownFrance: 527 citing papers, 4.4% of this breakdownJapan: 494 citing papers, 4.1% of this breakdownNetherlands: 480 citing papers, 4% of this breakdownSpain: 344 citing papers, 2.9% of this breakdownAustralia: 331 citing papers, 2.7% of this breakdownSwitzerland: 316 citing papers, 2.6% of this breakdown
0%24.1%Other 26%

Institutions

Fields

  • Medicine70.4%
  • Immunology and Microbiology17.3%
  • Biochemistry, Genetics and Molecular Biology8.1%
  • Neuroscience1.7%
  • Pharmacology, Toxicology and Pharmaceutics0.6%
  • Computer Science0.4%
  • Other1.5%

Topics

  • Rheumatoid Arthritis Research and Therapies13.3%
  • Systemic Lupus Erythematosus Research5.8%
  • Spondyloarthritis Studies and Treatments5.7%
  • Autoimmune and Inflammatory Disorders Research4.9%
  • T-cell and B-cell Immunology4%
  • Psoriasis: Treatment and Pathogenesis3.5%
  • Other62.8%

Coauthors

All papers

Open in search
  1. 2021 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis

    Authors: Liana Fraenkel, Joan M. Bathon, Bryant R. England, E. William St. Clair, Thurayya Arayssi, Kristine Carandang, Kevin D. Deane, Mark C. Genovese, K. Huston, Gail S. Kerr, Joel M. Kremer, Mary C. Nakamura, Linda Russell, Jasvinder A. Singh, Benjamin J. Smith, Jeffrey A. Sparks, Shilpa Venkatachalam, Michael E. Weinblatt, Mounir Al‐Gibbawi, Joshua F. Baker, Kamil E. Barbour, Jennifer L. Barton, Laura C. Cappelli, Fatimah Chamseddine, Michael George, Sindhu R. Johnson, Lara A Kahale, Basil S. Karam, Assem M. Khamis, Iris Navarro‐Millán, Reza Mirza, Pascale Schwab, Namrata Singh, Marat Turgunbaev, Amy S. Turner, Sally Yaacoub, Elie A. Akl - Arthritis & Rheumatology 2021 cited by 1,284

  2. Upadacitinib Versus Placebo or Adalimumab in Patients With Rheumatoid Arthritis and an Inadequate Response to Methotrexate: Results of a Phase III, Double‐Blind, Randomized Controlled Trial

    Authors: Roy Fleischmann, Aileen L. Pangan, In‐Ho Song, Eduardo Mysler, Louis Bessette, Charles Peterfy, Patrick Durez, Andrew J.K. Östör, Yihan Li, Yijie Zhou, Ahmed A. Othman, Mark C. Genovese - Arthritis & Rheumatology 2019 cited by 436

  3. Safety and efficacy of upadacitinib in patients with active rheumatoid arthritis refractory to biologic disease-modifying anti-rheumatic drugs (SELECT-BEYOND): a double-blind, randomised controlled phase 3 trial

    Authors: Mark C. Genovese, Roy Fleischmann, Bernard Combe, Stephen Hall, Andrea Rubbert‐Roth, Ying Zhang, Yijie Zhou, Mohamed‐Eslam F. Mohamed, Sebastian Meerwein, Aileen L. Pangan - The Lancet 2018 cited by 443

  4. Filgotinib versus placebo or adalimumab in patients with rheumatoid arthritis and inadequate response to methotrexate: a phase III randomised clinical trial

    Authors: Bernard Combe, Alan Kivitz, Yoshiya Tanaka, Désirée van der Heijde, J. Simón, Herbert S. B. Baraf, Uma Kumar, F. Matzkies, Beatrix Bartók, Lei Ye, Ying Guo, Chantal Tasset, John S. Sundy, Angelika Jahreis, Mark C. Genovese, Neelufar Mozaffarian, Robert Landewé, Sang‐Cheol Bae, Edward C. Keystone, Peter Nash - Annals of the Rheumatic Diseases 2021 cited by 247

  5. Effect of Filgotinib vs Placebo on Clinical Response in Patients With Moderate to Severe Rheumatoid Arthritis Refractory to Disease-Modifying Antirheumatic Drug Therapy

    Authors: Mark C. Genovese, Kenneth Kalunian, Jacques‐Eric Gottenberg, Neelufar Mozaffarian, Beatrix Bartók, F. Matzkies, Jie Gao, Ying Guo, Chantal Tasset, John S. Sundy, Kurt de Vlam, David Walker, Tsutomu Takeuchi - JAMA 2019 cited by 327

  6. Baricitinib in Patients with Refractory Rheumatoid Arthritis

    Authors: Mark C. Genovese, Joel Kremer, Omid Zamani, Charles Ludivico, Marek Krogulec, Li Xie, Scott D. Beattie, Alisa E. Koch, Tracy Cardillo, Terence Rooney, William L. Macias, Stephanie de Bono, Douglas Schlichting, Josef S Smolen - New England Journal of Medicine 2016 cited by 621

  7. Rituximab for rheumatoid arthritis refractory to anti–tumor necrosis factor therapy: Results of a multicenter, randomized, double‐blind, placebo‐controlled, phase III trial evaluating primary efficacy and safety at twenty‐four weeks

    Authors: Stanley Cohen, Paul Emery, Maria Greenwald, Maxime Dougados, Richard Furie, Mark C. Genovese, Edward Keystone, J. Loveless, Gerd‐Rüdiger Burmester, Matthew Cravets, E. Hessey, T Shaw, Mark C. Totoritis - Arthritis & Rheumatism 2006 cited by 1,640

  8. Safety and effectiveness of upadacitinib or adalimumab plus methotrexate in patients with rheumatoid arthritis over 48 weeks with switch to alternate therapy in patients with insufficient response

    Authors: Roy Fleischmann, Mark C. Genovese, Jeffrey Enejosa, Eduardo Mysler, Louis Bessette, Charles Peterfy, Patrick Durez, Andrew J.K. Östör, Yihan Li, In‐Ho Song - Annals of the Rheumatic Diseases 2019 cited by 174

  9. Safety Profile of Baricitinib in Patients with Active Rheumatoid Arthritis with over 2 Years Median Time in Treatment

    Authors: Josef S Smolen, Mark C. Genovese, Tsutomu Takeuchi, David L. Hyslop, William L. Macias, Terence Rooney, Lei Chen, Christina Dickson, Jennifer Riddle Camp, Tracy Cardillo, Taeko Ishii, Kevin Winthrop - The Journal of Rheumatology 2018 cited by 259

  10. Ixekizumab for the treatment of patients with active psoriatic arthritis and an inadequate response to tumour necrosis factor inhibitors: results from the 24-week randomised, double-blind, placebo-controlled period of the SPIRIT-P2 phase 3 trial

    Authors: Peter Nash, Bruce Kirkham, Masato Okada, Proton Rahman, Benard Combe, Gerd‐Ruediger Burmester, David Adams, Lisa Kerr, Chin Lee, Catherine L Shuler, Mark C. Genovese, Khalid Ahmed, Jeffrey Alper, N Barkham, Ralph E. Bennett, Francisco J. Blanco, Ricardo Blanco Alonso, Howard Blumstein, Michael S. Brooks, Gerd‐Rüdiger Burmester, Patricia Cagnoli, Paul H. Caldron, Alain Cantagrel, Der‐Yuan Chen, Melvin Churchill, Christine E. Codding, Benard Combe, Peter M.G. Deane, José Del Giudice, Atul Deodhar, Rajat K. Dhar, Eva Dokoupilová, Rita M. Egan, Andrea Everding, E. Galíndez, Mark C. Genovese, David H. Goddard, Alice B. Gottlieb, Philippe Goupille, Robert Griffin, Ramesh C. Gupta, Stephen Hall, Kalpita Hatti, Mary P. Howell, Yu‐Huei Huang, Ramina Jajoo, Namieta M. Janssen, Uta Kiltz, Alan Kivitz, Steven J. Klein, Mariusz Korkosz, Roshan Kotha, Joel M. Kremer, C Lue, José Luís Marenco de la Fuente, Helena Marzo‐Ortega, Jordi Gratacós Masmitja, Philip J. Mease, Pier Luigi Meroni, Eric C. Mueller, Anupama Nandagudi, Peter Nash, Antonio Fernández‐Nebro, C. Michael Neuwelt, Ana‐Maria Orbai, Meera R. Oza, Deborah L. Parks, Debendra Pattanaik, Maria Rell‐Bakalarska, David Rosmarin, Euthalia Roussou, Anna I. Rychlewska-Hanczewksa, David Sikes, Michael T. Stack, Prashanth Sunkureddi, Hasan Tahir, Diamant Thaçi, Tsen‐Fang Tsai, Anthony Turkiewicz, L. Unger, Raúl Veiga Cabello, Ulf Wagner, Cheng-Chung Wei, Alvin F. Wells, Peter Youssef, Agnieszka Zielińska - The Lancet 2017 cited by 405

  11. Safety and efficacy of neurostimulation with a miniaturised vagus nerve stimulation device in patients with multidrug-refractory rheumatoid arthritis: a two-stage multicentre, randomised pilot study

    Authors: Mark C. Genovese, Norman Gaylis, David Sikes, Alan Kivitz, Diane Horowitz, Charles Peterfy, Emmett V. Glass, Yaakov A. Levine, David Chernoff - The Lancet Rheumatology 2020 cited by 115

  12. Safety and efficacy of baricitinib at 24 weeks in patients with rheumatoid arthritis who have had an inadequate response to methotrexate

    Authors: Edward Keystone, Peter C. Taylor, Edit Drescher, Douglas Schlichting, Scott D. Beattie, Pierre‐Yves Berclaz, Chin H. Lee, Rosanne Fidelus-Gort, Monica Luchi, Terence Rooney, William L. Macias, Mark C. Genovese - Annals of the Rheumatic Diseases 2014 cited by 282

  13. Integrated safety analysis of filgotinib in patients with moderately to severely active rheumatoid arthritis receiving treatment over a median of 1.6 years

    Authors: Kevin Winthrop, Yoshiya Tanaka, Tsutomu Takeuchi, Alan Kivitz, F. Matzkies, Mark C. Genovese, Deyuan Jiang, Kun Chen, Beatrix Bartók, Angelika Jahreis, R. Besuyen, Gerd R Burmester, Jacques‐Eric Gottenberg - Annals of the Rheumatic Diseases 2021 cited by 79

  14. Fenebrutinib Versus Placebo or Adalimumab in Rheumatoid Arthritis: A Randomized, Double‐Blind, Phase II Trial

    Authors: Stanley Cohen, Katie Tuckwell, Tamiko R. Katsumoto, Rui Zhao, Joshua Galanter, Chin Lee, Julie Rae, Balázs István Tóth, Nandhini Ramamoorthi, Jason A. Hackney, Alberto Berman, Nemanja Damjanov, Dmytro Fedkov, Sławomir Jeka, Leslie W. Chinn, Michael J. Townsend, Alyssa Morimoto, Mark C. Genovese - Arthritis & Rheumatology 2020 cited by 118

  15. Abatacept for Rheumatoid Arthritis Refractory to Tumor Necrosis Factor α Inhibition

    Authors: Mark C. Genovese, Jean‐Claude Becker, Michael Schiff, Michael E. Luggen, Yvonne Sherrer, Joel Kremer, C. Birbara, J. Box, Kannan Natarajan, Isaac Nuamah, Tracy Li, Richard Aranda, David Hagerty, Maxime Dougados - New England Journal of Medicine 2005 cited by 1,245

  16. Tofacitinib in Combination With Nonbiologic Disease-Modifying Antirheumatic Drugs in Patients With Active Rheumatoid Arthritis

    Authors: Joel M. Kremer, Zhanguo Li, Stephen Hall, Roy Fleischmann, Mark C. Genovese, E. Martín‐Mola, John D. Isaacs, David Gruben, Gene V. Wallenstein, Sriram Krishnaswami, Samuel H. Zwillich, Tamás Koncz, Richard J. Riese, John Bradley - Annals of Internal Medicine 2013 cited by 447

  17. Non-invasive vagus nerve stimulation for rheumatoid arthritis: a proof-of-concept study

    Authors: Sara Marsal, Hèctor Corominas, Juan José de Agustín, Carolina Pérez-García, María López‐Lasanta, Helena Borrell, Dèlia Reina, Raimón Sanmartí, Javier Narváez, Clara Franco‐Jarava, Charles Peterfy, José Antonio Narváez, Vivek Kumar Sharma, Konstantinos Alataris, Mark C. Genovese, Matthew Baker - The Lancet Rheumatology 2021 cited by 70

  18. Clinical Efficacy and Safety of Baminercept, a Lymphotoxin β Receptor Fusion Protein, in Primary Sjögren's Syndrome

    Authors: E. William St. Clair, Alan N. Baer, Chungwen Wei, Ghaith Noaiseh, A. L. Parke, Andreea Coca, Tammy O. Utset, Mark C. Genovese, Daniel J. Wallace, James McNamara, Karen Boyle, Lynette Keyes‐Elstein, Jeffrey L. Browning, Nathalie Franchimont, Kira Smith, Joel M. Guthridge, Igñacio Sanz, Judith A. James - Arthritis & Rheumatology 2018 cited by 91

  19. Combination therapy with etanercept and anakinra in the treatment of patients with rheumatoid arthritis who have been treated unsuccessfully with methotrexate

    Authors: Mark C. Genovese, Stanley Cohen, Larry W. Moreland, D. Lium, Sean Robbins, Richard Newmark, Pirow Bekker, for the 20000223 Study Group - Arthritis & Rheumatism 2004 cited by 522

  20. Characterisation of the safety profile of evobrutinib in over 1000 patients from phase II clinical trials in multiple sclerosis, rheumatoid arthritis and systemic lupus erythematosus: an integrated safety analysis

    Authors: Xavier Montalbán, Daniel J. Wallace, Mark C. Genovese, Davorka Tomic, Dana Parsons‐Rich, Claire Le Bolay, Amy Kao, Hans Guehring - Journal of Neurology Neurosurgery & Psychiatry 2022 cited by 33

  21. Efficacy and Safety of ABT‐494, a Selective JAK‐1 Inhibitor, in a Phase IIb Study in Patients With Rheumatoid Arthritis and an Inadequate Response to Methotrexate

    Authors: Mark C. Genovese, Josef S Smolen, Michael E. Weinblatt, Gerd R Burmester, Sebastian Meerwein, Heidi S. Camp, Li Wang, Ahmed A. Othman, Nasser Khan, Aileen L. Pangan, Steven Jungerwirth - Arthritis & Rheumatology 2016 cited by 201

  22. Infections in baricitinib clinical trials for patients with active rheumatoid arthritis

    Authors: Kevin Winthrop, Masayoshi Harigai, Mark C. Genovese, Stephen Lindsey, Tsutomu Takeuchi, Roy Fleischmann, John Bradley, Nicole L Byers, David L. Hyslop, Maher Issa, Atsushi Nishikawa, Terence Rooney, Sarah Witt, Christina Dickson, Josef S Smolen, Maxime Dougados - Annals of the Rheumatic Diseases 2020 cited by 93

  23. Safety of ixekizumab in adult patients with plaque psoriasis, psoriatic arthritis and axial spondyloarthritis: data from 21 clinical trials

    Authors: Mark C. Genovese, Eduardo Mysler, Tetsuya Tomita, Kim Papp, Carlo Salvarani, Sergio Schwartzman, Gaia Gallo, Himanshu J. Patel, Jeffrey Lisse, Andris Kronbergs, Soyi Liu Leage, David H. Adams, Wen Xu, Helena Marzo‐Ortega, Mark Lebwohl - Lara D. Veeken 2020 cited by 71

  24. Phase II, randomised, double-blind, multicentre study evaluating the safety and efficacy of filgotinib and lanraplenib in patients with lupus membranous nephropathy

    Authors: Matthew Baker, Yashaar Chaichian, Mark C. Genovese, Vimal K. Derebail, Panduranga S. Rao, Winn Chatham, M Bubb, Sam Lim, Hooman Hajian, Oksana Gurtovaya, Uptal D. Patel, James A. Tumlin - RMD Open 2020 cited by 43